Trade Harvard Bioscience - HBIO CFD

Add to favourite

3.9295

3.68%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0510

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Harvard Bioscience Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	4.0795
Open*	4.0395
1-Year Change*	-17.79%
Day's Range*	3.8595 - 4.1595
52 wk Range	2.42-6.29
Average Volume (10 days)	74.18K
Average Volume (3 months)	1.78M
Market Cap	183.56M
P/E Ratio	-100.00K
Shares Outstanding	42.69M
Revenue	112.52M
EPS	-0.08
Dividend (Yield %)	N/A
Beta	1.48
Next Earnings Date	Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 17, 2024	4.0795	-0.0600	-1.45%	4.1395	4.3195	4.0395
Apr 16, 2024	4.1695	-0.1000	-2.34%	4.2695	4.3995	4.1395
Apr 15, 2024	4.4295	0.2600	6.24%	4.1695	4.4295	4.0995
Apr 12, 2024	4.2395	-0.0800	-1.85%	4.3195	4.4095	4.1695
Apr 11, 2024	4.3095	0.1800	4.36%	4.1295	4.3295	4.0495
Apr 10, 2024	4.2295	-0.2500	-5.58%	4.4795	4.5395	4.1395
Apr 9, 2024	4.6195	0.3100	7.19%	4.3095	4.6295	4.2495
Apr 8, 2024	4.2295	-0.2800	-6.21%	4.5095	4.5695	4.1795
Apr 5, 2024	4.4995	0.1700	3.93%	4.3295	4.4995	4.2095
Apr 4, 2024	4.4195	0.1200	2.79%	4.2995	4.6795	4.2695
Apr 3, 2024	4.1895	0.1000	2.45%	4.0895	4.1995	4.0695
Apr 2, 2024	4.1495	-0.0100	-0.24%	4.1595	4.2195	3.9895
Apr 1, 2024	4.2295	0.0200	0.48%	4.2095	4.2595	4.0895
Mar 28, 2024	4.2095	0.1300	3.19%	4.0795	4.2495	4.0695
Mar 27, 2024	4.1795	0.1000	2.45%	4.0795	4.1895	3.9195
Mar 26, 2024	4.0195	-0.0700	-1.71%	4.0895	4.1195	3.8895
Mar 25, 2024	4.1195	-0.1900	-4.41%	4.3095	4.3095	4.0895
Mar 22, 2024	4.1795	-0.1100	-2.56%	4.2895	4.2895	4.0395
Mar 21, 2024	4.3195	0.0500	1.17%	4.2695	4.3995	4.2095
Mar 20, 2024	4.3695	0.1300	3.07%	4.2395	4.3895	4.1795

Harvard Bioscience Events

Time (UTC)	Country	Event
Tuesday, April 23, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Harvard Bioscience Inc Earnings Release Q1 2024 Harvard Bioscience Inc Earnings Release Forecast - Previous -
Tuesday, May 14, 2024
Time (UTC) 15:00	Country US	Event Harvard Bioscience Inc Annual Shareholders Meeting Harvard Bioscience Inc Annual Shareholders Meeting Forecast - Previous -
Time (UTC) 15:00	Country US	Event Harvard Bioscience Inc Annual Shareholders Meeting Harvard Bioscience Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Harvard Bioscience Inc Earnings Release Q2 2024 Harvard Bioscience Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	113.335	118.904	102.1	116.176	120.774
Revenue	113.335	118.904	102.1	116.176	120.774
Cost of Revenue, Total	51.045	51.252	44.059	51.654	53.793
Gross Profit	62.29	67.652	58.041	64.522	66.981
Total Operating Expense	120.268	116.838	103.755	115.799	123.19
Selling/General/Admin. Expenses, Total	48.611	47.672	43.425	45.324	45.825
Research & Development	12.329	10.799	8.685	10.715	10.988
Depreciation / Amortization	6.122	5.84	5.71	5.746	5.384
Unusual Expense (Income)	2.161	1.275	1.876	2.36	7.2
Operating Income	-6.933	2.066	-1.655	0.377	-2.416
Interest Income (Expense), Net Non-Operating	-2.548	-1.54	-4.831	-5.41	-5.219
Other, Net	0.302	-0.666	-0.806	-0.469	-0.34
Net Income Before Taxes	-9.179	-0.14	-7.292	-5.502	-7.975
Net Income After Taxes	-9.516	-0.288	-7.81	-4.687	-4.299
Net Income Before Extra. Items	-9.516	-0.288	-7.81	-4.687	-4.299
Net Income	-9.516	-0.288	-7.81	-4.687	-2.922
Income Available to Common Excl. Extra. Items	-9.516	-0.288	-7.81	-4.687	-4.299
Income Available to Common Incl. Extra. Items	-9.516	-0.288	-7.81	-4.687	-2.922
Diluted Net Income	-9.516	-0.288	-7.81	-4.687	-2.922
Diluted Weighted Average Shares	41.413	40.343	38.64	37.814	36.453
Diluted EPS Excluding Extraordinary Items	-0.22978	-0.00714	-0.20212	-0.12395	-0.11793
Diluted Normalized EPS	-0.19586	0.0134	-0.13637	-0.08338	0.01045
Total Extraordinary Items				0	1.377

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	28.759	29.975	28.427	26.922	29.208
Revenue	28.759	29.975	28.427	26.922	29.208
Cost of Revenue, Total	12.086	11.629	12.594	14.75	12.571
Gross Profit	16.673	18.346	15.833	12.172	16.637
Total Operating Expense	27.963	28.226	28.884	30.684	25.21
Selling/General/Admin. Expenses, Total	11.531	12.312	11.811	12.143	12.568
Research & Development	2.957	2.897	2.849	2.763	3.497
Depreciation / Amortization	1.389	1.388	1.63	1.572	1.454
Unusual Expense (Income)	0	0	0	-0.544	-4.88
Operating Income	0.796	1.749	-0.457	-3.762	3.998
Interest Income (Expense), Net Non-Operating	-2.522	-0.974	-0.9	-0.749	-0.515
Other, Net	-0.372	0.432	0.465	-0.179	-0.062
Net Income Before Taxes	-2.098	1.207	-0.892	-4.69	3.421
Net Income After Taxes	-0.98	0.622	-1.666	-3.405	2.435
Net Income Before Extra. Items	-0.98	0.622	-1.666	-3.405	2.435
Net Income	-0.98	0.622	-1.666	-3.405	2.435
Income Available to Common Excl. Extra. Items	-0.98	0.622	-1.666	-3.405	2.435
Income Available to Common Incl. Extra. Items	-0.98	0.622	-1.666	-3.405	2.435
Diluted Net Income	-0.98	0.622	-1.666	-3.405	2.435
Diluted Weighted Average Shares	42.354	42.783	41.593	41.637	42.56
Diluted EPS Excluding Extraordinary Items	-0.02314	0.01454	-0.04005	-0.08178	0.05721
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.02314	0.01454	-0.04005	-0.09027	-0.01732

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	51.124	61.583	51.7	53.572	57.832
Cash and Short Term Investments	4.508	7.821	8.317	8.335	8.173
Cash & Equivalents	4.508	7.821	8.317	8.335	8.173
Total Receivables, Net	20.177	26.175	21.121	23.176	24.572
Accounts Receivable - Trade, Net	16.705	21.834	17.766	20.704	21.463
Total Inventory	26.439	27.587	22.262	22.061	25.087
Other Current Assets, Total
Total Assets	145.36	162.344	156.254	164.87	168.613
Property/Plant/Equipment, Total - Net	9.182	10.312	11.721	13.239	5.898
Property/Plant/Equipment, Total - Gross	24.028	24.761	28.318	28.179	23.336
Accumulated Depreciation, Total	-14.846	-14.449	-16.597	-14.94	-17.438
Goodwill, Net	56.26	57.689	58.59	57.381	57.304
Intangibles, Net	21.014	27.385	33.151	38.405	45.764
Other Long Term Assets, Total	7.78	5.375	1.092	2.273	1.815
Total Current Liabilities	23.249	25.316	21.053	25.312	25.489
Accounts Payable	6.447	4.911	5.972	5.339	7.359
Accrued Expenses	8.639	11.175	7.582	2.424	5.762
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	3.811	3.235	1.721	6.9	5.982
Other Current Liabilities, Total	4.352	5.995	5.778	10.649	6.386
Total Liabilities	73.14	78.943	79.573	83.176	85.889
Total Long Term Debt	43.013	45.095	46.286	46.917	54.813
Long Term Debt	43.013	45.095	46.286	46.917	54.813
Deferred Income Tax	0.59	1.558	1.899	1.974	2.301
Other Liabilities, Total	6.288	6.974	10.335	8.973	3.286
Total Equity	72.22	83.401	76.681	81.694	82.724
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.454	0.452	0.444	0.438	0.436
Additional Paid-In Capital	229.008	225.65	232.357	229.189	226.377
Retained Earnings (Accumulated Deficit)	-142.19	-132.674	-132.386	-124.576	-119.889
Treasury Stock - Common		0	-10.668	-10.668	-10.668
Other Equity, Total	-15.052	-10.027	-13.066	-12.689	-13.532
Total Liabilities & Shareholders’ Equity	145.36	162.344	156.254	164.87	168.613
Total Common Shares Outstanding	42.0817	41.1429	39.4071	38.1882	37.3788

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	50.486	52.617	52.449	51.124	51.818
Cash and Short Term Investments	5.34	4.324	3.789	4.508	5.144
Cash & Equivalents	5.34	4.324	3.789	4.508	5.144
Total Receivables, Net	19.328	22.204	21.799	20.177	20.558
Accounts Receivable - Trade, Net	14.983	16.903	17.737	16.705	15.023
Total Inventory	25.818	26.089	26.861	26.439	26.116
Total Assets	139.735	142.899	145.578	145.36	147.013
Property/Plant/Equipment, Total - Net	8.419	8.744	8.929	9.182	9.574
Goodwill, Net	56.222	56.771	56.618	56.26	54.851
Intangibles, Net	17.095	18.356	19.641	21.014	22.464
Other Long Term Assets, Total	7.513	6.411	7.941	7.78	8.306
Total Current Liabilities	24.205	22.942	23.217	23.249	21.36
Accounts Payable	6.269	4.716	5.978	6.447	5.877
Accrued Expenses	9.516	9.438	8.356	8.639	8.165
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	3.47	3.22	2.97	3.811	2.72
Other Current Liabilities, Total	4.95	5.568	5.913	4.352	4.598
Total Liabilities	65.449	67.511	71.238	73.14	75.034
Total Long Term Debt	35.273	38.203	41.083	43.013	46.534
Long Term Debt	35.273	38.203	41.083	43.013	46.534
Deferred Income Tax	0.661	0.667	0.546	0.59	1.181
Other Liabilities, Total	5.31	5.699	6.392	6.288	5.959
Total Equity	74.286	75.388	74.34	72.22	71.979
Preferred Stock - Non Redeemable, Net	0	0	0	0
Common Stock	0.457	0.457	0.455	0.454	0.453
Additional Paid-In Capital	232.896	231.533	230.108	229.008	228.229
Retained Earnings (Accumulated Deficit)	-143.787	-142.548	-141.568	-142.19	-140.524
Treasury Stock - Common
Other Equity, Total	-15.28	-14.054	-14.655	-15.052	-16.179
Total Liabilities & Shareholders’ Equity	139.735	142.899	145.578	145.36	147.013
Total Common Shares Outstanding	42.6883	42.6883	42.19	42.0817	41.6577

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-9.516	-0.288	-7.81	-4.687	-2.922
Cash From Operating Activities	1.152	1.262	9.331	8.045	2.884
Cash From Operating Activities	1.453	1.781	1.922	1.987	2.423
Amortization	6.122	5.84	5.71	5.746	5.459
Deferred Taxes	-0.414	-0.33	-0.143	-0.398	-2.861
Non-Cash Items	0.791	4.449	5.546	5.355	2.46
Cash Taxes Paid	0.534	0.577	0.416	0.374	-0.098
Cash Interest Paid	2.314	1.577	4.881	5.496	4.987
Changes in Working Capital	2.716	-10.19	4.106	0.042	-1.675
Cash From Investing Activities	-1.59	-1.345	-1.402	-0.229	-53.796
Capital Expenditures	-1.59	-1.345	-1.152	-1.216	-1.006
Other Investing Cash Flow Items, Total			-0.25	0.987	-52.79
Cash From Financing Activities	-2.837	-0.252	-7.967	-7.624	53.053
Issuance (Retirement) of Stock, Net	0.577	3.314			4.557
Issuance (Retirement) of Debt, Net	-1.786	0.05	-5.597	-7.403	48.496
Foreign Exchange Effects	-0.038	-0.161	0.02	-0.03	0.299
Net Change in Cash	-3.313	-0.496	-0.018	0.162	2.44
Financing Cash Flow Items	-1.628	-3.616	-2.37	-0.221

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	0.622	-9.516	-7.85	-4.445	-6.88
Cash From Operating Activities	1.812	1.152	-1.527	-2.176	-1.986
Cash From Operating Activities	0.333	1.453	1.122	0.758	0.382
Amortization	1.388	6.122	4.492	2.92	1.466
Non-Cash Items	0.765	0.791	-0.289	-1.498	0.97
Cash Taxes Paid	-0.134	0.534	0.493	0.352	0.107
Cash Interest Paid	1.172	2.314	1.529	0.845	0.383
Changes in Working Capital	-1.296	2.716	1.158	-0.951	2.076
Cash From Investing Activities	0.288	-1.59	-1.355	-0.913	-0.471
Capital Expenditures	-0.224	-1.59	-1.355	-0.913	-0.471
Cash From Financing Activities	-2.893	-2.837	-0.107	-0.484	0.094
Financing Cash Flow Items	-0.156	-1.628	-1.167	-0.78	-0.501
Issuance (Retirement) of Stock, Net	0.104	0.577	0.346	0.282	0.031
Issuance (Retirement) of Debt, Net	-2.841	-1.786	0.714	0.014	0.564
Foreign Exchange Effects	0.074	-0.038	0.312	0.011	-0.025
Net Change in Cash	-0.719	-3.313	-2.677	-3.562	-2.388
Deferred Taxes		-0.414	-0.16	1.04
Other Investing Cash Flow Items, Total	0.512

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Harvard Bioscience Company profile

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harvard Bioscience, Inc. revenues increased 16% to $118.9M. Net loss decreased 96% to $288K. Revenues reflect United States segment increase of 18% to $49.8M, Europe segment increase of 19% to $35.8M. Lower net loss reflects Interest expense decrease of 68% to $1.5M (expense), G/L on early Exting of lease relat debt decrease from $1.9M (expense) to $0K.

Equity composition

Common Stock $.01 Par, 12/10, 80M auth., 36,057,974 issd., less 7,745,507 shs. in Treas. @ 10.7M. Insiders & Strategic holders own 13.56%. IPO: 12/7/2000, 6,420,000 shs. @$8 by Thomas Weisel Partners LLC. *NOTE: 10/02, Company acquired Genomic Solutions, Inc. @ 0.1017 shares and $0.286 in cash (3,178,857 shares issd.).

Industry:

Advanced Medical Equipment & Technology (NEC)

84 October Hill Rd
HOLLISTON
MASSACHUSETTS 01746-1371
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024